- Home
- PBYI vs CLDT Comparison
PBYI vs CLDT Comparison
Compare PBYI & CLDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | CLDT |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 660.3M |
| IPO Year | 2011 | 2009 |
Fundamental Metrics
Financial Performance| Metric | PBYI | CLDT |
|---|---|---|
| Price | $8.22 | $16.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 410.6K | ★ 504.0K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.52% |
| EPS Growth | N/A | ★ 275.00 |
| EPS | ★ 0.20 | 0.11 |
| Revenue | $27,685,000.00 | ★ $295,075,000.00 |
| Revenue This Year | N/A | $9.69 |
| Revenue Next Year | $1.33 | $3.41 |
| P/E Ratio | ★ $105.13 | $143.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.76 | $6.38 |
| 52 Week High | $11.50 | $16.30 |
Technical Indicators
Market Signals| Indicator | PBYI | CLDT |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 82.26 |
| Support Level | $7.64 | $12.36 |
| Resistance Level | $8.53 | N/A |
| Average True Range (ATR) | 0.53 | 0.48 |
| MACD | -0.33 | 0.13 |
| Stochastic Oscillator | 14.61 | 95.32 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CLDT Chatham Lodging Trust (REIT) of Beneficial Interest
Chatham Lodging Trust is a U.S.-based real estate investment trust that invests in upscale extended-stay hotels. The firm operates across various states in the U.S., including California, New York, Texas, Florida, Minnesota, Massachusetts, and Pennsylvania, among others. Substantially all of the company's assets are held and operated by its operating partnership, Chatham Lodging, LP. Chatham Lodging LP and its subsidiaries lease the overall company's hotels. Chatham's revenue streams include room, food and beverage, and other. The room comprises the majority of its total revenue. Chatham's hotels operate under various brands, which include Hilton, Marriott, and Hyatt.